Learn More about Lumida ETF
Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home Lifestyle Health and Longevity

One-Third of Americans Now Use AI for Health Advice — and Many Are Skipping the Doctor

by Team Lumida
March 31, 2026
in Health and Longevity
Reading Time: 4 mins read
A A
0
One-Third of Americans Now Use AI for Health Advice — and Many Are Skipping the Doctor
Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp

Key Takeaways

  • Roughly 1 in 3 U.S. adults have used AI to find health information, with nearly 30% seeking physical health advice and 1 in 6 turning to AI for mental health questions — making AI as common a health resource as social media, according to a new KFF poll of more than 1,300 adults.
  • More than 40% of health AI users have uploaded personal medical data — including test results and doctor’s notes — into AI tools, even as more than three-quarters of all adults say they are very or somewhat concerned about health data privacy.
  • About 1 in 5 AI health users cited inability to get an appointment or lack of a provider as a major driver — signaling that AI is increasingly filling access-to-care gaps rather than simply supplementing routine medical consultations.
  • Younger adults and low-income individuals are most likely to use AI for health questions and least likely to follow up with a provider afterward — raising concerns that AI may be widening rather than bridging healthcare equity gaps.

What Happened?

A new poll from KFF, the nonpartisan health policy research organization, finds that approximately one-third of U.S. adults have used AI tools to seek health information — a level of adoption that now rivals social media as a source of health guidance. The survey, conducted among more than 1,300 adults, found that 29% had used AI for physical health information in the past year and 1 in 6 had used it for mental health queries. The most cited reason for using AI was the desire for quick health advice, followed by researching information before a doctor’s visit. However, a significant minority — about 1 in 5 users — said they turned to AI specifically because they lacked a provider or couldn’t secure an appointment, underlining AI’s growing role as a substitute for, not just a supplement to, professional medical care. The poll also found that about 6 in 10 adults who used AI for physical health advice subsequently saw a doctor, and 4 in 10 sought a mental health professional — but younger adults were considerably less likely to make that follow-up visit.

Why It Matters?

For investors in healthcare AI and digital health, the KFF poll provides some of the most concrete market sizing data yet for the consumer health AI category. OpenAI, Microsoft, and Amazon have all launched health-specific AI tools in recent months, betting on exactly this kind of mass adoption. The 40%-plus rate of personal medical data uploads into AI tools is particularly significant: it suggests consumers are already treating these platforms as quasi-medical record repositories, creating both a competitive moat for the platforms that capture this data and a serious regulatory risk as the FTC, HHS, and state attorneys general scrutinize AI health data practices. The finding that younger, lower-income users are most likely to use AI as a primary — not supplementary — healthcare resource raises important equity and liability questions. If AI health tools give misleading or incomplete advice to populations that are least likely to follow up with a clinician, the public health consequences could be significant and the legal exposure for AI companies could be material.

What’s Next?

The health AI market is accelerating on multiple fronts simultaneously. OpenAI’s health-specific ChatGPT launched in January, Microsoft’s dedicated health AI chatbot followed in March, and Amazon expanded its health-focused AI assistant the same month — suggesting the competitive intensity will only increase. Regulatory clarity, however, is lagging: the FDA has begun scrutinizing AI clinical decision support tools but has not yet established clear standards for consumer-facing health AI. The data privacy concern flagged by KFF — more than 75% of adults worried about personal health data in AI systems — is a regulatory flashpoint that could trigger HIPAA-adjacent legislation if a major data breach occurs. For investors evaluating healthcare AI plays, the key metrics to watch are not just user numbers but follow-up care conversion rates, data upload penetration, and whether platforms can monetize the health data they’re collecting without triggering a regulatory or reputational crisis.


Source: https://www.healthcaredive.com/news/kff-poll-ai-health-information-adults/744217/

Previous Post

The Iran War’s Invisible Casualty: A Helium Crisis That Could Cripple AI Chips and MRI Scanners

Next Post

Wall Street Just Wrapped Its Worst Quarter in Four Years — and Investors Are Bracing for Worse

Recommended For You

Novo Nordisk’s $10 Billion Cardiovascular Bet Fails — Ziltivekimab Misses Heart Attack and Stroke Endpoint, Stock Drops 10.5%

by Team Lumida
2 days ago
Novo Nordisk Q2 2024 Earnings Highlights

Novo Nordisk's experimental drug ziltivekimab — a monthly IL-6 inhibitor injection targeting cardiovascular disease, chronic kidney disease, and inflammation in a market Jefferies estimates at $10B+ annually —...

Read more

Trump Administration to End $3.6 Billion Medicare Drug Premium Subsidy — Seniors Face Higher Part D Costs in 2027

by Team Lumida
4 days ago
Supreme Court Signals It Will Strike Down Trump’s Birthright Citizenship Order

The Trump administration will not renew the Part D Low Income Premium Subsidy program after 2026, eliminating $3.6 billion in annual payments to insurers that have been holding...

Read more

80% of People Are Deficient in Essential Vitamins — Here Are the 10 You Actually Need and Where to Get Them

by Team Lumida
6 days ago
oranges, peas, and limes on a wooden table

Most people are not getting enough of the 13 essential vitamins their bodies require — here is a practical guide to the most critical nutrients, what they do,...

Read more

Whoop Enters Clinical Care With Joint Replacement Recovery Pilot — Can Wearable Biometrics Reduce Opioids and Speed Recovery?

by Team Lumida
2 weeks ago
a close up of a human skull on a black background

Whoop and surgical software company Kinomatic have launched a 12-week pilot program called Restore across three California orthopedic clinics to test whether continuous biometric monitoring — heart rate...

Read more

$399 Signal Ring Claims to Replace the Blood Pressure Cuff — No Calibration, No Subscription, Clinical Trial at Stanford

by Team Lumida
2 weeks ago
Fingers hold a black smart ring with circuits visible.

Vital Signals, a three-year-old startup, has launched a $399 Signal Ring that claims to track blood pressure as accurately as a traditional arm cuff — without requiring any...

Read more

Novo’s Obesity Pill Commands 89% Market Share — Lilly’s Foundayo Captures Just 11% After Three Months on Market

by Team Lumida
3 weeks ago
Novo’s Obesity Pill Commands 89% Market Share — Lilly’s Foundayo Captures Just 11% After Three Months on Market

Novo Nordisk's Wegovy pill has seized 89% of new oral obesity pill prescriptions since its January 2026 launch, leaving Eli Lilly's Foundayo — launched in April — with...

Read more

Information Blocking in Healthcare Is Down — But a Stubborn Minority of IT Vendors Keep Doing It Routinely

by Team Lumida
3 weeks ago
doctor holding red stethoscope

The share of health information exchanges reporting instances of information blocking fell from over 90% in 2019 to 71% in 2025, according to new ONC data — but...

Read more

Novo Nordisk Squeezes Suppliers for Discounts as Eli Lilly Eats Its Lunch in the Obesity Drug Market

by Team Lumida
1 month ago
Novo Nordisk Q2 2024 Earnings Highlights

Novo Nordisk has written to suppliers seeking price discounts to protect its cost base as it fights to claw back market share lost to Eli Lilly in the...

Read more

Medicare Launches $50/Month Weight-Loss Drug Coverage Today — With Caveats

by Team Lumida
1 month ago
GLP-1 Drugs Are Triggering a Returns Crisis for America’s Apparel Retailers

Medicare's "Bridge" program kicks off July 1, offering Wegovy and Zepbound to 12.5–20 million eligible seniors at a $50 monthly copay — down from up to $450 cash...

Read more

FDA Reverses Rejection of Regenxbio Gene Therapy for Fatal Rare Disease

by Team Lumida
1 month ago
FDA Reverses Rejection of Regenxbio Gene Therapy for Fatal Rare Disease

The FDA agreed to reverse its rejection of Regenxbio's Navsunli gene therapy for Hunter syndrome — the third rare-disease drug reversal under new FDA leadership, marking a retreat...

Read more
Next Post
AI Job-Loss Panic Is Running Ahead of the Data, Says Bloomberg Opinion

Wall Street Just Wrapped Its Worst Quarter in Four Years — and Investors Are Bracing for Worse

McCormick to Buy Unilever’s $15.7B Food Empire in a Deal That Reshapes the Global Pantry

McCormick to Buy Unilever's $15.7B Food Empire in a Deal That Reshapes the Global Pantry

Related News

Lumida Wealth Whale Watch Q2’24 : Stock Picker Funds

September 26, 2024
Anthropic Wins Partial Victory in AI Copyright Case, Setting Precedent for Future Rulings

Anthropic Wins Partial Victory in AI Copyright Case, Setting Precedent for Future Rulings

June 25, 2025

Nasdaq Pushes Toward Near-24/5 Stock Trading, Seeking SEC Approval for 23-Hour Weekdays

December 16, 2025

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Latest
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips Amazon Apple Artificial Intelligence Banking Bitcoin China Commercial Real Estate CPI Crypto data centers Donald Trump EARNINGS ELON MUSK ETF Ethereum Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Intel Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Nvidia OpenAI private equity S&P 500 SEC stock market Tech Stocks tesla Trump Wells Fargo Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018